Use with caution in cardiovascular disease (myocardial infarction, arrhythmia). Should not be used postpartum in women with coronary artery disease or other cardiovascular disease (its use to control or prevent lactation or in uncontrolled hypertension is not recommended). Ergot alkaloids and derivatives have been associated with fibrotic valve thickening (e.g. aortic, mitral, tricuspid), usually associated with long-term, chronic use. Symptomatic hypotension may occur. Concomitant use of bromocriptine and other ergot alkaloids is not recommended. Particular caution is indicated in patients who have recently received other drugs that can alter blood pressure. Associated with compulsive behaviors and/or loss of impulse control (pathological gambling, libido increases, and/or binge eating). May cause sudden sleep onset and somnolence, primarily in Parkinson’s disease. Confusion and mental disturbances may occur in patients with parkinsonian syndrome receiving high-dose therapy. Concurrent use with levodopa has been associated with an increased risk of hallucinations. Caution in dementia. Discontinuation of therapy in macroadenomas has been associated with rapid regrowth of tumor and increased prolactin serum levels. Digital vasospasm (cold-sensitive) may occur in some patients with acromegaly. Rare cases of pleural and/or retroperitoneal fibrosis reported with prolonged daily use. Use with caution in peptic ulcer disease. Use not recommended in galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption. Use with caution in hepatic/renal impairment. Bromocriptine therapy has caused transient increases in serum concentrations of AST (SGOT), ALT (SGPT), γ-glutamyl transferase (γ-glutamyltranspeptidase, GGT, GGTP), creatine kinase (CK, creatine phosphokinase, CPK), alkaline phosphatase, uric acid, and BUN. May interfere with TSH assay (false low TSH levels).